Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension

Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension

Trifluoperazine (TFP), an antipsychotic drug approved by the Food and Drug Administration, has been show to exhibit anti-cancer effects. Pulmonary arterial hypertension (PAH) is a devastating disease characterized by a progressive obliteration of small pulmonary arteries (PAs) due to exaggerated pro...

Full description

Bibliographic Details
Main Authors: Yann Grobs, Charifa Awada, Sarah-Eve Lemay, Charlotte Romanet, Alice Bourgeois, Victoria Toro, Valérie Nadeau, Kana Shimauchi, Mark Orcholski, Sandra Breuils-Bonnet, Eve Tremblay, Steeve Provencher, Roxane Paulin, Olivier Boucherat, Sébastien Bonnet
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:International Journal of Molecular Sciences
Subjects:
vascular remodeling
FOXO3
autophagy
smooth muscle cells
drug repositioning
Online Access:https://www.mdpi.com/1422-0067/22/6/2919

Internet

https://www.mdpi.com/1422-0067/22/6/2919

Similar Items